Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …

Reactive oxygen species (ROS) have emerged as essential signaling molecules regulating
cell survival, death, inflammation, differentiation, growth, and immune response …

Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

Parkinson's disease (PD) is a complex syndrome with many elements, such as chronic
inflammation, oxidative stress, mitochondrial dysfunction, loss of dopaminergic neurons …

Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States
Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus …

Abstract Glucagon-like peptide 1 (GLP-1) analogues have been commercialized for the
management of type 2 diabetes. Recent studies have underscored GLP-1's role as a …

Background Parkinson's disease (PD) is the second most common, and the fastest‐growing
neurodegenerative disorder with unclear etiology in most cases. Therefore, the identification …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonist-based drugs (incretin mimetics)
have meaningfully impacted current treatment of type 2 diabetes mellitus (T2DM), and their …

Background: Parkinson's disease (PD) is a progressive neurodegenerative movement
disorder that afflicts more than 10 million people worldwide. Available therapeutic …

Drugs like Semaglutide (aka Ozempic/Wegovy) that activate the glucagon-like peptide-1
receptor (GLP1R) are a promising therapy for obesity and type 2 diabetes (T2D). Animal …